Ten years of proteomics in multiple sclerosis

Proteomics

Volumn 14, Issue 4-5, 2014, Pages 467-480

  Farias, Alessandro S ^a   Pradella, Fernando ^a   Schmitt, Andrea ^b,c   Santos, Leonilda M B ^a   Martins de Souza, Daniel ^b,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomedicine; EAE; Inflammation; Multiple sclerosis; Neurodegeneration

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C9; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA A ANTIGEN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 7 RECEPTOR ALPHA; OLIGOCLONAL BAND; PROSTAGLANDIN D2; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; CD6 ANTIGEN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3;

BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CYTOKINE RELEASE; DEMYELINATING DISEASE; ENVIRONMENTAL FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FAMILY HISTORY; FIRST DEGREE RELATIVE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HUMAN; INCIDENCE; INFLAMMATION; MEMBRANE DAMAGE; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; X CHROMOSOME; COGNITIVE DEFECT; MASS SPECTROMETRY; PHYSICAL DISABILITY; SMOKING;

BIOMEDICINE; EAE; INFLAMMATION; MULTIPLE SCLEROSIS; NEURODEGENERATION;

AXONS; BIOLOGICAL MARKERS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; PROTEOMICS;

EID: 84896693634     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300268     Document Type: Review

References (113)

1. Hauser, S. L., Oksenberg, J. R., The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52, 61-76.
2. Hafler, D. A., Slavik, J. M., Anderson, D. E., O'Connor, K. C. et al., Multiple sclerosis. Immunol. Rev. 2005, 204, 208-231.
3. Lassmann, H., Multiple sclerosis: is there neurodegeneration independent from inflammation? J. Neurol. Sci. 2007, 259, 3-6.
4. Kieseier, B. C., Wiendl, H., Leussink, V. I., Stuve, O., Immunomodulatory treatment strategies in multiple sclerosis. J. Neurol. 2008, 255, 15-21.
5. Nylander, A., Hafler, D. A., Multiple sclerosis. J. Clin. Invest. 2012, 122, 1180-1188.
6. Lassmann, H., van Horssen, J., Mahad, D., Progressive multiple sclerosis: pathology and pathogenesis. Nat. Rev. Neurol. 2012, 8, 647-656.
7. Sadovnick, A. D., Dyment, D. A., Ebers, G. C., Risch, N. J., Evidence for genetic basis of multiple sclerosis. Lancet 1996, 347, 1728-1730.
8. Dyment, D. A., Ebers, G. C., Sadovnick, A. D., Genetics of multiple sclerosis. Lancet Neurol. 2004, 3, 104-110.
9. Munger, K. L., Zhang, S. M., O'Reilly, E., Hernan, M. A. et al., Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62, 60-65.
10. Ramagopalan, S. V., Anderson, C., Sadovnick, A. D., Ebers, G. C., Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007, 357, 2199-2200.
11. Apperson, M. L., Tian, Y., Stamova, B., Ander, B. P. et al., Genome wide differences of gene expression associated with HLA-DRB1 genotype in multiple sclerosis: a pilot study. J. Neuroimmunol. 2013, 257, 90-96.
12. Haines, J. L., Ter-Minassian, M., Bazyk, A., Gusella, J. F. et al., A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet. 1996, 13, 469-471.
13. International Multiple Sclerosis Genetics Consortium, Genome-wide association study of severity in multiple sclerosis. Genes Immun. 2011, 12, 615-625.
14. International Multiple Sclerosis Genetics Consortium, Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15, 000 Cases and 30, 000 Controls. Am. J. Hum. Genet. 2013, 92, 854-865.
15. Patsopoulos, N. A., Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist, ANZgene Consortium, et al., Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann. Neurol. 2011, 70, 897-912.
16. Baranzini, S. E., Nickles, D., Genetics of multiple sclerosis: swimming in an ocean of data. Curr. Opin. Neurol. 2012, 25, 239-245.
17. Noseworthy, J. H., Bass, B. H., Vandervoort, M. K., Ebers, G. C. et al., The prevalence of primary sjogren's syndrome in a multiple sclerosis population. Ann. Neurol. 1989, 25, 95-98.
18. Nielsen, N. M., Westergaard, T., Frisch, M., Rostgaard, K. et al., Type 1 diabetes and multiple sclerosis: a Danish population-based cohort study. Arch. Neurol. 2006, 63, 1001-1004.
19. Compston, A., Coles, A., Multiple sclerosis. Lancet 2002, 359, 1221-1231.
20. Roosendaal, S., Geurts, J., Vrenken, H., Hulst, H. et al., Regional DTI differences in multiple sclerosis patients. NeuroImage 2009, 44, 1397-1403.
21. De Stefano, N., Matthews, P. M., Filippi, M., Agosta, F. et al., Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003, 60, 1157-1162.
22. Geurts, J. J. G., Bö, L., Pouwels, P. J. W., Castelijns, J. A. et al., Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am. J. Neuroradiol. 2005, 26, 572-577.
23. Pirko, I., Lucchinetti, C. F., Sriram, S., Bakshi, R., Gray matter involvement in multiple sclerosis. Neurology 2007, 68, 634-642.
24. Fisniku, L. K., Chard, D. T., Jackson, J. S., Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann. Neurol. 2008, 64, 247-254
25. Dalton, C. M., Chard, D. T., Davies, G. R., Miszkiel, K. A. et al., Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004, 127, 1101-1107.
26. Fisher, E., Lee, J. C., Nakamura, K., Rudick, R. A., Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 2008, 64, 255-265.
27. Brownell, B., Hughes, J. T., The distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Pschiatr. 1962, 25, 315-320.
28. Rivers, T. M., Sprunt, D. H., Berry, G. P., Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58, 39-53.
29. Baxter, A. G., The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7, 904-912.
30. Farias, A. S., Talaisys, R. L., Blanco, Y. C., Lopes, S. C. P. et al., Regulatory T cell induction during Plasmodium chabaudi infection modifies the clinical course of experimental autoimmune encephalomyelitis. PLoS ONE 2011, 6, e17849.
31. Farias, A. S., Spagnol, G. S., Bordeaux-Rego, P., Oliveira, C. O. F. et al., Vitamin D3 inducesIDO(+) tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci. Ther. 2013, 19, 269-277.
32. Flugel, A., Willem, M., Berkowicz, T., Wekerle, H., Gene transfer into CD4+ T lymphocytes: green fluorescent protein-engineered, encephalitogenic T cells illuminate brain autoimmune responses. Nat. Med. 1999, 5, 843-847.
33. Kuchroo, V. K., Martin, C. A., Greer, J. M., Ju, S. T. et al., Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 1993, 151, 4371-4382.
34. Steinman, L., A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat. Med. 2007, 13, 139-145.
35. O'Connor, R. A., Prendergast, C. T., Sabatos, C. A., Lau, C. W. Z. et al., Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181, 3750-3754.
36. Bartholomäus, I., Kawakami, N., Odoardi, F., Schläger, C. et al., Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462, 94-98.
37. Pradella, F., Moraes, A. S., Santos, M. P. A., Depaula, R. F. O. et al., Granulocyte colony-stimulating factor treatment enhances Foxp3(+) T lymphocytes and modifies the proinflammatory response in experimental autoimmune neuritis. CNS Neurosci. Ther. 2013, 19, 529-532.
38. Emamaullee, J. A., Davis, J., Merani, S., Toso, C. et al., Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58, 1302-1311.
39. Korn, T., Bettelli, E., Oukka, M., Kuchroo, V. K., IL-17 and Th17 Cells. Annu. Rev. Immunol. 2009, 27, 485-517.
40. Flugel, A., Berkowicz, T., Ritter, T., Labeur, M. et al., Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001, 14, 547-560.
41. Kang, Z., Liu, L., Spangler, R., Spear, C. et al., IL-17-induced Act1-mediated signaling is critical for cuprizone-induced demyelination. J. Neurosci. 2012, 32, 8284-8292.
42. Farias, A. S., La Hoz, de, C., Castro, F. R., Oliveira, E. C. et al., Nitric oxide and TNFalpha effects in experimental autoimmune encephalomyelitis demyelination. Neuroimmunomodulat. 2007, 14, 32-38.
43. Goverman, J., Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9, 393-407.
44. Plant, S. R., Iocca, H. A., Wang, Y., Thrash, J. C. et al., Lymphotoxin β receptor (LtβR): dual roles in demyelination and remyelination and successful therapeutic intervention using LtβR-Ig protein. J. Neurosci. 2007, 27, 7429-7437.
45. Fabis, M. J., Scott, G. S., Kean, R. B., Koprowski, H., Hooper, D. C., Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 5656-5661.
46. Bettini, M., Vignali, D. A., Regulatory T cells and inhibitory cytokines in autoimmunity. Curr. Opin. Immunol. 2009, 21, 612-618.
47. Wing, K., Sakaguchi, S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11, 7-13.
48. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 2008, 133, 775-787.
49. Hori, S., Nomura, T., Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057-1061.
50. Kitani, A., Chua, K., Nakamura, K., Strober, W., Activated self-MHC-reactive T cells have the cytokine phenotype of Th3/T regulatory cell 1 T cells. J. Immunol. 2000, 165, 691-702.
51. Carrier, Y., Yuan, J., Kuchroo, V. K., Weiner, H. L., Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J. Immunol. 2007, 178, 172-178.
52. Jaros, J. A., Guest, P. C., Bahn, S., Martins-de-Souza, D. Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. Methods Mol. Biol. 2013, 1002, 1-11.
53. Koutroukides, T. A., Guest, P. C., Leweke, F. M., Bailey, D. M. D. et al., Characterization of the human serum depletome by label-free shotgun proteomics. J. Sep. Science 2011, 34, 1621-1626.
54. Dagley, L. F., Emili, A., Purcell, A. W., Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Prot. Clin. Appl. 2013, 7, 91-108.
55. Nilsson, C., Lindvall-Axelsson, M., Owman, C., Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Brain Res. Rev. 1992, 17, 109-138.
56. Polman, C. H., Reingold, S. C., Banwell, B., Wu, Q., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69, 292-302
57. Hsueh, C. J., Kao, H. W., Chen, S. Y., Lo, C. P. et al., Comparison of the 2010 and 2005 versions of the McDonald MRI criteria for dissemination-in-time in Taiwanese patients with classic multiple sclerosis. J. Neurol. Sci. 2013, 329, 51-54.
58. Link, H., Huang, Y. M., Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 2006, 180, 17-28.
59. Sartori, S., Priante, E., Pettenazzo, A., Marson, P. et al., Intrathecal synthesis of oligoclonal bands in rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome: new evidence supporting immunological pathogenesis. J. Child Neurol. 2013, DOI 10.1177/0883073812469050.
60. Ticozzi, N., Tiloca, C., Mencacci, N. E., Morelli, C. et al., Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. J. Neurol. 2013, 260, 85-92.
61. Haghighi, S., Andersen, O., Nilsson, S., Rydberg, L., Wahlström, J., A linkage study in two families with multiple sclerosis and healthy members with oligoclonal CSF immunopathy. Mult. Scler. 2006, 12, 723-730.
62. Glehn, von, F., Farias, A. S., de Oliveira, A. C. P., Damasceno, A. et al., Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult. Scler. 2012, 18, 1038-1041.
63. Archelos, J. J., Hartung, H. P., Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 2000, 23, 317-327.
64. Haase, C. G., Schmidt, S., Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100β and myelin basic protein in patients with Devic's neuromyelitis optica. Neurosci. lett. 2001, 307, 131-133
65. Oliveira, E. C., Fujisawa, M. A. R. M., Hallal Longo, D. E. M., Farias, A. S. et al., Neuropathy of gastrointestinal chagas' disease: immune response to myelin antigens. Neuroimmunomodulation 2009, 16, 54-62.
66. Martins-de-Souza, D., Guest, P. C., Vanattou-Saifoudine, N., Harris, L. W., Bahn, S., Proteomic technologies for biomarker studies in psychiatry: advances and needs. Int. Rev. Neurobiol. 2011, 101, 65-94.
67. Brewis, I. A., Brennan, P., Proteomics technologies for the global identification of proteins. Adv. Protein. Chem. Struct. Biol. 2010, 80, 1-44.
68. Anderson, N. L., Anderson, N. G., The Human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
69. Colten, H. R., Rosen, F. S., Complement deficiencies. Annu. Rev. Immunol. 1992, 10, 809-834.
70. Ricciotti, E., FitzGerald, G. A., Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 986-1000.
71. York, I. A., Rock, K. L., Antigen processing and presentation by the class I major histocompatibility complex 1. Annu. Rev. Immunol. 1996, 14, 369-396.
72. Tumani, H., Hartung, H. P., Hemmer, B., Teunissen, C., Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35, 117-127.
73. Reiber, H., Ungefehr, S., Jacobi, C., The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 1998, 4, 111-117.
74. Ayoglu, B., Haggmark, A., Khademi, M., Olsson, T. et al., Autoantibody profiling in multiple sclerosis using arrays of human protein fragments. Mol. Cell. Proteomics 2013, 12, 2657-2672.
75. Mahley, R. W., Weisgraber, K. H., Huang, Y., Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 5644-5651.
76. Mahley, R. W., Huang, Y., Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 2012, 76, 871-885.
77. Vitek, M. P., Brown, C. M., Colton, C. A., APOE genotype-specific differences in the innate immune response. Neurobiol. Aging 2009, 30, 1350-1360.
78. Laskowitz, D. T., Lee, D. M., Schmechel, D., Staats, H. F., Altered immune responses in apolipoprotein E-deficient mice. J. Lipid Res. 2000, 41, 613-620.
79. Perretti, M., D'Acquisto, F., Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat. Rev. Immunol. 2009, 9, 62-70.
80. Chiara, A. D., Pederzoli-Ribeil, M., Burgel, P. R., Danel, C., Witko-Sarsat, V., Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation. Front. Immunol. 2012, 3, 311.
81. Farias, A. S., Martins-de-Souza, D., Guimarães, L., Pradella, F. et al., Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. Proteomics 2012, 12, 2656-2662.
82. Norgren, N., Sundstrom, P., Svenningsson, A., Rosengren, L. et al., Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63, 1586-1590.
83. Sofroniew, M. V., Reactive astrocytes in neural repair and protection. Neuroscientist 2005, 11, 400-407.
84. Castegna, A., Thongboonkerd, V., Klein, J. B., Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 2003, 27, 630-633.
85. Vosler, P. S., Brennan, C. S., Chen, J., Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol. 2008, 38, 78-100.
86. Ray, S., Banik, N., Calpain and Its Involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpain inhibitors for prevention of neurodegeneration. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 173-189.
87. Rosenberg, G. A., Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009, 8, 205-216.
88. Srivastava, R., Aslam, M., Kalluri, S. R., Schirmer, L. et al., Potassium channel KIR4.1 as an immune target in multiple sclerosis. N. Engl. J. Med. 2012, 367, 115-123.
89. Oliveira, B. M., Schmitt, A., Falkai, P., Daniel Martins-de-Souza. Is clinical proteomics heading towards to "Bench to Bedside?" Transl. Proteomics 2013, 1, 53-66.
90. Vanheel, A., Daniels, R., Plaisance, S., Baeten, K. et al., Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One 2012, 7, e35544.
91. Comabella, M., Fernández, M., Martin, R., Rivera-Vallvé, S. et al., Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010, 133, 1082-1093.
92. Ottervald, J., Franzén, B., Nilsson, K., Andersson, L. I. et al., Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers. J. Proteomics 2010, 73, 1117-1132.
93. Stoop, M. P., Dekker, L. J., Titulaer, M. K., Burgers, P. C. et al., Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8, 1576-1585.
94. Stoop, M. P., Singh, V., Dekker, L. J., Titulaer, M. K. et al., Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5, e12442.
95. Liu, S., Bai, S., Qin, Z., Yang, Y., Cui, Y., Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J. Cell Mol. Med. 2009, 13, 1586-1603.
96. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
97. Linker, R. A., Brechlin, P., Jesse, S., Steinacker, P. et al., Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage. PLoS One 2009, 4, e7624.
98. Ly, L., Barnett, M. H., Zheng, Y. Z., Gulati, T. et al., Comprehensive tissue processing strategy for quantitative proteomics of formalin-fixed multiple sclerosis lesions. J. Proteome Res. 2011, 10, 4855-4868.
99. Rithidech, K. N., Honikel, L., Milazzo, M., Madigan, D. et al., Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult. Scler. 2009, 15, 455-464.
100. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
101. Rosenling, T., Stoop, M. P., Attali, A., Aken, H. V. et al., Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J. Proteome Res. 2012, 11, 2048-2060.
102. Liu, T., Donahue, K. C., Hu, J., Kurnellas, M. P. et al., Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6, 2565-2575.
103. De Masi, R., Vergara, D., Pasca, S., Acierno, R. et al., PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: a pilot study on relation to clinical findings and brain atrophy. J. Neuroimmunol. 2009, 210, 80-86.
104. Kroksveen, A. C., Opsahl, J. A., Aye, T. T., Ulvik, R. J., Berven, F. S., Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J. Proteomics 2011, 74, 371-388.
105. Dumont, D., Noben, J. P., Raus, J., Stinissen, P., Robben, J., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
106. Jastorff, A. M., Haegler, K., Maccarrone, G., Holsboer, F. et al., Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Prot. Clin. Appl. 2009, 3, 1273-1287.
107. Broadwater, L., Pandit, A., Clements, R., Azzam, S. et al., Analysis of the mitochondrial proteome in multiple sclerosis cortex. Biochim. Biophys. Acta 2011, 1812, 630-641.
108. Almeras, L., Lefranc, D., Drobecq, H., de Seze, J. et al., New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004, 4, 2184-2194.
109. Jain, M. R., Bian, S., Liu, T., Hu, J. et al., Altered proteolytic events in experimental autoimmune encephalomyelitis discovered by iTRAQ shotgun proteomics analysis of spinal cord. Proteome Sci. 2009, 7, 1-10.
110. Fazeli, A. S., Nasrabadi, D., Sanati, M. H., Pouya, A. et al., Proteome analysis of brain in murine experimental autoimmune encephalomyelitis. Proteomics 2010, 10, 2822-2832.
111. Lehmensiek, V., Süssmuth, S. D., Tauscher, G., Brettschneider, J. et al., Cerebrospinal fluid proteome profile in multiple sclerosis. Mult. Scler. 2007, 13, 840-849.
112. Fainardi, E., Castellazzi, M., Tamborino, C., Trentini, A. et al., Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult. Scler. 2009, 15, 547-554.
113. Liu, J., Yin, L., Dong, H., Xu, E. et al., Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls. J. Neuroimmunol. 2012, 250, 71-76.